

SLE: KOL Insight [2017]

<https://marketpublishers.com/r/S8BD92A8793EN.html>

Date: June 2017

Pages: 0

Price: US\$ 8,145.00 (Single User License)

ID: S8BD92A8793EN

Abstracts

Will novel therapies revolutionise the treatment of SLE?

With the approval of GSK's Benlysta (belimumab) came the dawn of targeted therapy in the treatment of systemic lupus erythematosus (SLE). Roche's Rituxan/MabThera (rituximab), now experiencing biosimilar competition in Europe, is also used off-label. Despite these advances significant unmet need remains in the treatment of SLE. Novel products are on the horizon, including anifrolumab (BMZ/AstraZeneca), forigerimod (ImmunPharma) and voclosporin (Aurinia Pharma), but challenges in the development of novel SLE treatments mean that nothing should be taken for granted. Learn how KOLs see the market evolving, and how they expect developers to differentiate their pipeline therapies in KOL Insight: Systemic Lupus Erythematosus (SLE). Twelve North American and European KOLs give their insight on one marketed product, one off-label product and 10 pipeline programmes. KOLs also provide their candid views on the potential for novel mechanisms of action.

Contents

1.EXECUTIVE SUMMARY

2.RESEARCH OBJECTIVES AND FOCUS

2.1 Research objectives

2.2 Research focus

3. MARKET OVERVIEW

3.1 Key insights summary

4. APPROVED STANDARD OF CARE THERAPIES

4.1 Key insights summary

4.1.1 Overview

5. APPROVED AND OFF-LABEL TARGETED THERAPIES

5.1 Benlysta (belimumab; GSK)

5.1.1 Key insights summary

5.1.2 Drug summary

5.2 Rituxan/MabThera (rituximab; Roche/Biogen)

5.2.1 Key insights summary

5.2.2 Drug summary

6.LATE-STAGE PIPELINE PROGRAMMES

6.1 Challenges in the clinical development of novel SLE treatments

6.1.1 British Isles Lupus Assessment Group (BILAG) index and BILAG-2004

6.1.2 SLEDAI, SLEDAI-2000, SELENA-SLEDAI

6.1.3 CLASI

6.1.4 Systemic Lupus Activity Measure

6.1.5 SLE Responder Index

6.1.6 BILAG-Based Composite Lupus Assessment

6.2 Anifrolumab (BMS/AstraZeneca)

6.2.1 Key insights summary

6.2.2 Drug summary

6.3 Lupuzor (forigerimod; ImmuPharma)

6.3.1 Key insights summary

6.3.2 Drug summary

6.4 Abatacept (Orencia; BMS)

6.4.1. Key insights summary

6.4.2 Drug summary

6.5 Voclosporin (Aurinia Pharma)

6.5.1 Key insights summary

6.5.2 Drug summary

7. EARLY STAGE DEVELOPMENT PROGRAMMES

7.1 Baricitinib (Olumiant; Eli Lilly)

7.1.1 Key insights summary

7.1.2 Drug summary

7.2 BIIB-059 (Biogen)

7.2.1 Key insights summary

7.2.2 Drug summary

7.3 Obinutuzumab (Gazyva/Gazyvaro; Roche)

7.3.1 Key insights summary

7.3.2 Drug summary

7.4 Lulizumab pegol (BMS-931699; BMS)

7.4.1 Key insights summary

7.4.2 Drug summary

7.5 Dapirolizumab pegol (CDP-7657; Biogen/UCB)

7.5.1 Key insights summary

7.5.2 Drug summary

7.6 Ustekinumab (Stelara; Janssen Biotech)

7.6.1 Key insights summary

7.6.2 Drug summary

7.7 Theralizumab (TAB-08; TheraMAB)

7.7.1 Key insights summary

7.7.2 Drug summary

8. INSIGHTS ON FAILED DEVELOPMENT PROGRAMMES

8.1 Blisibimod (AMG-623; Anthera Pharmaceuticals)

8.1.1 Key insights summary

8.1.2 Drug summary

9.FUTURE TREATMENT PARADIGM

9.1 Key insights summary

9.2 Overview

10. CONCLUSION

11. APPENDIX

11.1 KOL biographies

11.1.1 North American KOLs

11.1.2 European KOLs

I would like to order

Product name: SLE: KOL Insight [2017]

Product link: <https://marketpublishers.com/r/S8BD92A8793EN.html>

Price: US\$ 8,145.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S8BD92A8793EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970